Leiden, February 14, 2022 – MIMETAS has just attended the annual SLAS International Conference and Exhibition in person, which took place on February 5-9, 2022, in Boston, Massachusetts. This flagship conference connects great minds in life sciences and technology with each other and with the innovation, technology, and automation needed to transform research each year. We would like to look back on this wonderful week.
MIMETAS at SLAS 2022
Organ-on-a-chip (OoaC) models improve the human physiological relevance of cultured tissues and have better predictive ability than conventional models for drug screening. Making OoaC systems such as the OrganoPlate® platform available for automation and high-throughput drug screening purposes would offer the scalability and usability needed for pharmaceutical use. This will help make strides in accelerating drug development and contribute to understanding the pathophysiology of disease.
This year, MIMETAS held an in-person booth for attendees to visit and speak with subject-matter experts. Attendees could also delve into the latest advancements in our ground-breaking tissue and disease models in revolutionizing drug discovery and development through different educational content and activities. Here is a brief overview of them:
- “High throughput phenotypic screening with Organ-on-a-Chip: Future? Reality!”
This Exhibitor Tutorial was delivered by MIMETAS, and featured experts from Molecular Devices and Merck KgaA. The tutorial showcased how OoaC technology is enabling scientists to develop relevant disease models in a platform that is fully compatible with automated imaging and robotic handling for improved drug development. - “Organ-on-a-chip meets high throughput screening: measuring transendothelial electrical resistance”
This poster presentation demonstrated the applicability of the OrganoTEER instrument to study of low Trans Epithelial Electrical Resistance values in endothelial models. - “A robotised 1546 compound screen in a perfused 3D microfluidic angiogenesis assay”
This poster presentation elaborated on the high-throughput value of OrganoPlate 3-lane 64 platform, and how it was used to execute a robotized 1546 compound screen on a 3D angiogenic sprouting assay. This is the largest compound screen conducted with OoaC to date. - “Automation of the organ-on-a-chip assay: automated culture, imaging, and analysis of angiogenesis”
This poster was presented by our partners, Molecular Devices and co-authored with MIMETAS and Beckman Coulter Life Sciences. The poster presentation described a workflow for automation organ-on-a-chip culture, as well as monitoring and automation cell analysis. The method utilizes an integrated work-cell consisting of several instruments. - In collaboration with Molecular Devices, we also produced a new video to highlight how the automated workflow of the OrganoPlate platform, which is made possible with Molecular Device's cutting edge techonlogy, addresses key challenges of scaling complex 3D biology.
- We also announced the release of our new OrganoTEER 3-lane 64, which can augment and accelerate the readouts of TEER on 64 samples, and allows automated measurements of high- and low- TEER of endothelial and epithelial cultures under flow conditions and in real-time.
Do you want to learn how we can support your research or drug screening efforts? Get in touch with us!
